MedPath

To Find the Effect of LION’S MANE TABLET as a Nutritional Supplement

Phase 2/3
Completed
Conditions
Diabetes mellitus due to underlying condition without complications. Ayurveda Condition: Systemic hypertension or Diabetes Mellitus or Hyperlipidemia.,
Registration Number
CTRI/2022/03/040733
Lead Sponsor
DXN Manufacturing India Pvt Ltd
Brief Summary

The subjects who fulfilled the inclusion and exclusion criteria will be enrolled in the study. The selected subjects will receive Lions’s Mane Tablet (Hericium Erinaceus) two tablets each three times after breakfast, lunch and dinner daily for 4 weeks. The Patients will be on standard treatment for other co morbid conditions as per standard guidelines.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
24
Inclusion Criteria
  • 1.Participants aged 18-60 years (both sex).
  • 2.Participants who are determined to be at risk for malnutrition based on the Malnutrition Screening Tool for adults and presenting with any one of the co morbidities like Systemic hypertension or Diabetes Mellitus or Hyperlipidemia.
Exclusion Criteria
  • Participants presenting with fever and acute infections, will be excluded.
  • History of heart, liver or kidney failure.
  • Allergy or intolerance to the individual constituents in test product.
  • Patients with history of thyroid abnormalities.
  • Patients with history of any malignancy.
  • Organ transplantation 8.
  • Allergy to fungi 9.
  • Subjects who are pregnant and lactating mothers, or with any serious disease condition limiting full adhesion to the protocol.
  • Participation in an investigational drug trial in the 30 days prior to the screening visit.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Improvement in the nutritional status based on Malnutrition screening tool, Mini Nutritional assessment & DETERMINE Your nutritional health checklist. [Baseline, week 4]Day 0 and 28
2.Improvement in Cognitive function by using Montreal Cognitive Assessment [Baseline and week 4]Day 0 and 28
Secondary Outcome Measures
NameTimeMethod
1.Improvement in BMI and mid arm circumference and various hematological and biochemical blood parameter will be monitored2.Adverse event monitoring

Trial Locations

Locations (2)

PM Medical Centre Vellore

🇮🇳

Vellore, TAMIL NADU, India

Smiriti’s Clinic

🇮🇳

Kancheepuram, TAMIL NADU, India

PM Medical Centre Vellore
🇮🇳Vellore, TAMIL NADU, India
Dr Ramesh Kannan
Principal investigator
9677786447
srkguruvarshan@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.